On Monday, Cullinan Therapeutics Inc (NASDAQ: CGEM) opened higher 7.80% from the last session, before settling in for the closing price of $16.02. Price fluctuations for CGEM have ranged from $7.64 to $30.19 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -20.00%. Company’s average yearly earnings per share was noted 18.87% at the time writing. With a float of $39.16 million, this company’s outstanding shares have now reached $42.90 million.
Let’s determine the extent of company efficiency that accounts for 85 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Cullinan Therapeutics Inc (CGEM) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Cullinan Therapeutics Inc is 32.77%, while institutional ownership is 77.64%. The most recent insider transaction that took place on Nov 05 ’24, was worth 125,120. In this transaction Chief Scientific Officer of this company sold 8,000 shares at a rate of $15.64, taking the stock ownership to the 107,942 shares. Before that another transaction happened on Sep 05 ’24, when Company’s Chief Scientific Officer sold 8,000 for $18.09, making the entire transaction worth $144,720. This insider now owns 115,942 shares in total.
Cullinan Therapeutics Inc (CGEM) Earnings and Forecasts
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.54 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.96) by 0.42. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.85 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 18.87% per share during the next fiscal year.
Cullinan Therapeutics Inc (NASDAQ: CGEM) Trading Performance Indicators
Check out the current performance indicators for Cullinan Therapeutics Inc (CGEM). In the past quarter, the stock posted a quick ratio of 24.46.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.88, a number that is poised to hit -0.79 in the next quarter and is forecasted to reach -3.09 in one year’s time.
Technical Analysis of Cullinan Therapeutics Inc (CGEM)
Looking closely at Cullinan Therapeutics Inc (NASDAQ: CGEM), its last 5-days average volume was 0.71 million, which is a jump from its year-to-date volume of 0.66 million. As of the previous 9 days, the stock’s Stochastic %D was 51.42%. Additionally, its Average True Range was 0.95.
During the past 100 days, Cullinan Therapeutics Inc’s (CGEM) raw stochastic average was set at 39.19%, which indicates a significant decrease from 90.23% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 55.22% in the past 14 days, which was lower than the 56.24% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $16.78, while its 200-day Moving Average is $18.52. However, in the short run, Cullinan Therapeutics Inc’s stock first resistance to watch stands at $17.84. Second resistance stands at $18.42. The third major resistance level sits at $19.33. If the price goes on to break the first support level at $16.35, it is likely to go to the next support level at $15.44. Should the price break the second support level, the third support level stands at $14.86.
Cullinan Therapeutics Inc (NASDAQ: CGEM) Key Stats
There are currently 57,977K shares outstanding in the company with a market cap of 1.03 billion. Presently, the company’s annual sales total 0 K according to its annual income of -153,160 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -42,030 K.
